Lavie O, et al. - Among 779 Jewish patients with invasive epithelial ovarian cancer, researchers compared 5-, 10- and 15-year survival between those with and without BRCA1/2 germ line mutation. The study population included 229 carriers to the Ashkenazi Jewish founder mutations in BRCA1 (185delAG; 5382insC) and BRCA2 (6174delT) as well as 550 non-carriers. Using patients' medical records, clinical features were studied. Using the National Population Registry, vital status was updated. Survival analyses were carried out using Kaplan-Meier method, log-rank tests, and Cox-regression model. Up to 20 years follow-up findings were analyzed. During the first 5 years, a survival advantage was observed among BRCA1/2 carriers, which then decreased over time.